National Graphite Corp. (NGRC) Research

National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.

Market snapshot

Symbol
NGRC
Price
$0.03
Day change
0.00%
Market cap
$4.5M
P/E ratio
-78.56x
52-week range
0.016-0.05
Sector
Financial Services
Industry
Shell Companies

Peer companies

  • Arsenal Digital Holdings, Inc. (ADHI)
  • Ameriguard Security Services, Inc. (AGSS)
  • Arax Holdings Corp. (ARAT)
  • AVVAA World Health Care Products, Inc. (AVVH)
  • Broadcast Marketing Group, Inc. (BDCM)
  • Forwardly Inc. (FORW)
  • LZG International, Inc. (LZGI)
  • Metavesco, Inc. (MVCO)

Open National Graphite Corp. (NGRC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.